AbbVie UK publishes 2017 transparency data

Press Releases   •   Jun 29, 2018 12:25 BST

AbbVie annual transparency publication of transfer of value data to healthcare professionals, healthcare organisations and patient organisation goes live 29 June 2018.

AbbVie UK Launches Third Annual ‘Big Ideas for Better Health’ Awards

Press Releases   •   May 22, 2018 05:00 BST

-Awards celebrate forward-thinking individuals and teams who are championing innovation and supporting the NHS to become more resilient and sustainable -Independent judging panel led by Patients Association -Winning teams receive £3000 bursary to spread their work

AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

Press Releases   •   May 02, 2018 10:10 BST

• Application supported by four pivotal Phase 3 trials evaluating patients with moderate to severe plaque psoriasis (refs 1-3) • Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit (ref 4) and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing

New Presentation, HUMIRA® (adalimumab) 20 mg/0.2 mL for Injection in Pre-filled Syringe (PFS) Launched for Paediatric Patients, together with the Introduction of Fixed Weight Dosing

Press Releases   •   Mar 29, 2018 16:06 BST

Maidenhead, UK, 29th March 2018 – AbbVie a global research and development-based biopharmaceutical company, today announced the launch of HUMIRA® (adalimumab) 20 mg/0.2 mL presentation. The presentation is designed for injection in a pre-filled syringe specifically in paediatric patients for approved indications (paediatric polyarticular juvenile idiopathic arthritis, paediatric enthesitis related arthritis, paediatric Crohn’s disease, paediatric plaque psoriasis and paediatric Uveitis).

The formulation contains the same active ingredient, adalimumab, and the efficacy and safety profile remains unchanged. In 2016 AbbVie introducted a citrate free adalimumab 100 mg/mL formulation and launched Humira 40 mg/0.4 mL. The HUMIRA 20 mg/0.2 mL will be available to the UK Market at the beginning of quarter two (April 2018).

"The launch of the HUMIRA 20 mg/0.2 mL presentation underscores our ongoing dedication to improving the patient experience through research and enhancements,” said Alice Butler, Medical Director, AbbVie. “We remain committed to innovation in immunology in order to improve upon the therapeutic experience of patients and physicians.”

Professor Ramanan, Consultant Paediatric Rheumatologist, Bristol Royal Hospital for Children & Royal National Hospital for Rheumatic Diseases, said: “The introduction of HUMIRA 20 mg/0.2 mL is welcome news for paediatric patients, that will provide significant reduction in pain on administration for paediatric patients”.

Kit Tranter, Lead Paediatric Rheumatology Nurse Specialist at Jenny Lind Children's Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust said: “This will be met positively by the Paediatric Nursing community as the implications for empowering young people and their families, improving quality of life by reducing the technical nature of administering paediatric doses, reducing waste whilst maintaining good control of long term conditions shouldn’t be underestimated. I’m delighted that the specific needs of the paediatric rheumatology patient group have been recognised and acted upon to improve the overall experience”.

The paediatric dosing has been simplified. Instead of using body surface area as a calculation of dose required, the calculation is based on age and weight and will utlilise the newly available HUMIRA 20 mg/0.2mL and current HUMIRA 40 mg/0.4 mL.

-ENDS-


Notes to editors

About HUMIRA® (adalimumab)

For further information, and recommended dosing of HUMIRA for each paediatric indication, please see the Summary of Product Characteristics: http://www.medicines.org.uk/emc.

Important EU Safety Information

HUMIRA is contraindicated in patients with active tuberculosis or other severe infections such as sepsis, and opportunistic infections and in patients with moderate to severe heart failure (NYHA class III/IV). It is also contraindicated in patients hypersensitive to the active substance or to any of the excipients. The use of HUMIRA increases the risk of developing serious infections which may, in rare cases, be life threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with HUMIRA. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache and musculoskeletal pain.

###

UK Media Contacts

Cheryl Pitcher Email: cheryl.pitcher@abbvie.com

Tel: 07500 786 466

References:

1) HUMIRA [Summary of Product Characteristics]. AbbVie Ltd.; Available at: https://www.medicines.org.uk/emc/search?q=humira. Accessed 28th March 2018.

Date of preparation: March 2018

Zinc reference no: AXHUM180208

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

Maidenhead, UK, 29th March 2018 – AbbVie a global research and development-based biopharmaceutical company, today announced the launch of HUMIRA® (adalimumab) 20 mg/0.2 mL presentation. The presentation is designed for injection in a pre-filled syringe specifically in paediatric patients for approved indications.

Read more »

AbbVie’s Duodopa® (levodopa-carbidopa intestinal gel) recommended for use within NHS Wales

Press Releases   •   Mar 27, 2018 09:46 BST

MAIDENHEAD, UK, 26 March 2018 – AbbVie, a global research and development-based biopharmaceutical company, today announced that its advanced Parkinson’s therapy, Duodopa®, has been recommended for use within NHS Wales, following an assessment by the All Wales Medicines Strategy Group (AWMSG)1. Levodopa-carbidopa intestinal gel is recommended for the treatment of advanced levodopa-responsive Parkinson’s with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results, and when patients are not eligible for deep brain stimulation.

AbbVie UK General Manager, Jerome Bouyer, said: “We welcome the news that the AWMSG has recommended Duodopa® for this population of patients with advanced Parkinson’s. NHS Health Boards in Wales must now ensure that the therapy is made available within the statutory two months of the publication of the final guidance, as mandated by the Wales new treatment fund. A small number of patients rely on Duodopa® so it’s critical that they get swift access to the therapy that they need.”

The projected 2018 prevalence of Parkinson’s in Wales is 7,6922 .Parkinson’s is a condition that leads to a loss of the chemical dopamine in the brain, which controls movement and balance.3Levodopa-carbidopa intestinal gel is administered directly through the intestine, bypassing the stomach, and may be prescribed for some people with Parkinson’s who have tried other combinations of medicines but do not have satisfactory control of their motor symptoms (movement and balance).4

Steve Ford, Chief Executive, Parkinson’s UK commented: “This is good news for people living with advanced Parkinson’s in Wales, some of whom may have no other viable treatment option available to them.”

Levodopa-carbidopa intestinal gel (LCIG) contains the medicines levodopa and carbidopa. LCIG is delivered continuously and directly into the intestine via a tube that passes through the abdominal wall. LCIG is delivered via a pump that is carried by the patient during the day. If medically justified, LCIG may also be administered during the night.4

Levodopa-carbidopa intestinal gel is not suitable for all patients and therefore the SmPC should be referred to for full details and side effects. Please visit https://www.medicines.org.uk/emc/product/6231.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AbbVie UK Ltd. Please contact ukadverseevents@abbvie.com. With biological medicines, healthcare professionals should report adverse reactions by brand name and batch number.

-ENDS-

Notes to editors

About Parkinson’s

  • The projected 2018 prevalence of Parkinson’s in Wales is 7,6922 .Parkinson’s is a condition in which part of the brain becomes progressively damaged over many years. Itis caused by a loss of nerve cells in the part of the brain responsible for producing a chemical called dopamine. Dopamine plays a vital role in regulating the movement of the body and a reduction in dopamine is responsible for many of the symptoms of Parkinson's disease.3
  • The main symptoms of Parkinson's are tremor, rigidity and slowness of movement, these are often called motor symptoms.As well as affecting movement, people with Parkinson's can find that other issues, such as tiredness, pain, depression and constipation, can have an impact on their day-to-day lives. The symptoms someone has and how quickly the condition develops will differ from one person to the next. Most people with Parkinson’s start to develop symptoms when they’re over 50, although around 1 in 20 people with the condition first experience symptoms when they’re under 40.3
  • The term 'advanced Parkinson's' usually refers to a time when symptoms are more complex and have more of an effect on day-to-day life.People at this stage may find that they are no longer able to do tasks such as washing and dressing without help from someone else, perhaps a carer. Around 10% per cent of people with Parkinson’s progress toadvanced stage.5

UK media contacts

Sarah Beck

sarah.beck@abbvie.com

+44 (0)7818 428111

References

1 AWMSG Final Appraisal Recommendation, ref 3397 http://www.awmsg.org/awmsgonline/app/appraisalinfo/3397, (last accessed, March 2018)

2 Parkinson’s UK, The Incidence and Prevalence of Parkinson’s in the UK; Results from the Clinical Practice Research Datalink Summary report http://www.parkinsons.org.uk/sites/default/files/2018-01/CS2960%20Incidence%20and%20prevalence%20report%20branding%20summary%20report.pdf(last accessed, March 2018)

3 NHS Choices. Parkinson’s Disease http://www.nhs.uk/Conditions/Parkinsons-disease/Pages/Introduction.aspx (last accessed, March 2018)

4 Electronic Medicines Compendium, Duodopa Summary of Product Characteristics

https://www.medicines.org.uk/emc/product/6231 (last accessed, March 2018)

5 Worth P. When the going gets tough: how to select patients with Parkinson’s disease for advanced therapies, Pract. Neurol. 2013;0:1-13

About AbbVie

AbbVie is a global, research and development biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

All Wales Medicines Strategy Group (AWMSG) recommends levodopa-carbidopa intestinal gel as an option for the treatment of advanced Parkinson’s in patients not eligible for deep brain stimulation

Read more »

NEARLY TWO THIRDS PUT OFF SEEING DOCTORS DUE TO DIAGNOSIS FEARS – NEW QUIZ LAUNCHED TODAY TO UNDERSTAND WHY

Press Releases   •   Feb 15, 2018 00:01 GMT

New ‘Crush Your FOFO’ quiz will help experts and the public better understand FOFO which is preventing people from seeking medical advice

NICE recommends AbbVie’s HUMIRA® (adalimumab) for treatment of non-infectious uveitis

Press Releases   •   Feb 12, 2018 13:42 GMT

  • NICE publishes guidance recommending AbbVie’s HUMIRA® (adalimumab) as an option for treating eligible adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids1
  • Non-infectious uveitis can lead to reduced vision or vision loss and is the third-leading cause of preventable blindness worldwide2,3
  • Adalimumab is the first and only biologic medicine licensed for adult patients with certain types of non-infectious uveitis

MAIDENHEAD, UK, 26 July 2017 – AbbVie, a global biopharmaceutical company, today announced that the National Institute for Health and Care Excellence (NICE) has recommended HUMIRA® (adalimumab) as a clinically and cost effective treatment option for eligible adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids1.

Uveitis is an uncommon group of inflammatory eye conditions which can be caused either by infection or abnormal activation of the immune system in the uvea, the middle part of the eye4,5. Non-infectious uveitis can lead to reduced vision or vision loss and is the third-leading cause of preventable blindness worldwide2,3. It can affect both children and adults and is more common in people with an existing inflammatory or autoimmune condition5.

This NICE Technology Appraisal Guidance (TAG), which also provides recommendations on the use of dexamethasone, follows the publication of the ‘Interim Clinical Commissioning Policy Statement: Adalimumab for Severe Refractory Uveitis’ in March 20176. It means that, for eligible patients, routine treatment is not limited to steroids and/or immunosuppressants. Treatment with steroids can be associated with a number of complications, therefore patients who have had an inadequate response to or who are intolerant to steroids and/or immunosuppressants may require another treatment option to control the inflammation in the eye5,7. Adalimumab is the first and only biologic medicine licensed for adult patients with certain types of non-infectious uveitis (intermediate, posterior and pan-uveitis).

Annie Folkard, Co-Founder, Birdshot Uveitis Society said, “We are delighted that there is now another treatment option for those adults with severe uveitis who have not responded to other forms of treatment and who are at greatest risk of going blind. The effects of uveitis can be devastating. Not only can it make everyday tasks very difficult, but uncontrolled uveitis can also lead to irreversible deterioration of vision and ultimately blindness.”

Jessica Hall, RNIB Eye Health Policy Officer, said: “We very much welcome NICE’s recommendations as we finally have a routinely available treatment option, which has been shown to be safe and effective for those adults most at risk of sight loss.”

Mr Fahd Quhill, Consultant Ophthalmologist, Royal Hallamshire Hospital said, “Uveitis can be difficult to diagnose and treat, but due to its potentially life-long impact and the risk of complications it’s essential that the condition is treated effectively and inflammation is controlled. This new NICE guidance represents significant progress for those uveitis patients most at risk of going blind.”

This NICE TAG recommends adalimumab as an option for treating non-infectious uveitis in the posterior segment of the eye in adults with inadequate response to corticosteroids, only if there is: active disease; inadequate response or intolerance to immunosuppressants; systemic disease or both eyes are affected; and worsening vision with a high risk of blindness1.

When NICE recommends a treatment ‘as an option’, the NHS is required to comply with the recommendations and make it available for eligible patients in England and Wales within 3 months of the guidance being published1.

The NICE TAG recommendation for adalimumab is based on efficacy and safety data from two randomised controlled trials, VISUAL-I and VISUAL-II. The studies demonstrated that adult patients with either active or controlled non-infectious intermediate, posterior and panuveitis treated with adalimumab had a significantly lower risk for uveitic flare or decrease in visual acuity, compared to placebo8,9.

-ENDS-

Notes to editors

About adalimumab

For further information, please see the Summary of Product Characteristics:

http://www.medicines.org.uk/emc

About RNIB

Every 15 minutes, someone in the UK begins to lose their sight. We are the Royal National Institute of Blind People (RNIB) and we're here for everyone affected by sight loss - that's almost 2 million people in the UK. If you, or someone you know, has a sight problem, RNIB can help. Call the RNIB Helpline on 0303 123 9999 or visit www.rnib.org.uk

References:

1 National Institute for Health and Care Excellence. Adalimumab and dexamethasone for treating non-infectious uveitis Technology appraisal guidance [TA460]. July 2017. Available at: www.nice.org.uk/guidance/ta460 [Last accessed: July 2017].

2 Durrani OM, et al. Degree, duration, and causes of visual loss in uveitis. British Journal of Ophthalmology 2004;88:1159-1162.

3 Siddique SS, et al. Glaucoma and Uveitis. Survey of Ophthalmology 2013;58(1-10).

4 Jabs DA, et al. Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. American Journal of Ophthalmology 2005;140(3):509-516.

5 Guly CM and Forrester JV. Investigation and Management of Uveitis. BMJ 2010;341:821-826.

6 NHS England, Specialised Services Clinical Reference Group for Specialised Ear and Ophthalmology CRG, ‘Interim Clinical Commissioning Policy Statement: Adalimumab with Severe Refractory Uveitis’. Available at: https://www.england.nhs.uk/wp-content/uploads/2017/03/clin-com-pol-statment-170010ps.pdf. [Last accessed: July 2017].

7 McCluskey PJ, et al. Management of Chronic Uveitis. BMJ 2000;320:555-558.

8 Jaffe GJ, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 2016;375(10):932-43.

9 Nguyen QD, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet 2016;388:1183-1192.

 AXHUR171031

Date of prep: July 2017

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

NICE publishes guidance recommending AbbVie’s HUMIRA® (adalimumab) as an option for treating eligible adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids

Read more »

Response To Announcement Of NHS England’s Plans To Be First In The World To Eliminate Hepatitis C

Press Releases   •   Jan 26, 2018 08:46 GMT

MAIDENHEAD, UK, January 28, 2017 – We welcome NHS England’s announcement of their plans towards the elimination of hepatitis C in England and we are encouraged to see a commitment being made for the long-term. This follows the lead of industry’s multi-billion investment in the development of curative treatments for patients, and also our work with partners to diagnose and find those that remain undiagnosed, estimated to be half of the 160,000 affected by hepatitis C in England. 

Since curative treatments became available in 2015, AbbVie has been seeking ways of making cure sustainable for the NHS and we continue to invest in advancing patient pathways and services, through collaborating with multilateral groups including patient organisations, drug & alcohol services and prisons. Sustained, long-term commitment to the funding of these elements is just as critical as the procurement of medicines if the NHS in England is to realise its ambitious vision to eliminate hepatitis C five years earlier than the World Health Organization’s 2030 goal; a goal which we support. 

We have been working closely and collaboratively with NHS England to build towards the elimination strategy and will continue to do so in order to find sustainable approaches to funding and increased access to treatments and services for all those affected by hepatitis C.

AXHCV180095 Date of preparation: January 2018

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

MAIDENHEAD, UK, January 28, 2017 – We welcome NHS England’s announcement of their plans towards the elimination of hepatitis C in England and we are encouraged to see a commitment being made for the long-term.

Read more »

AbbVie announces phase III data showing VENCLYXTO®▼(venetoclax) in combination with rituximab improves progression-free survival in previously treated chronic lymphocytic leukaemia

Press Releases   •   Dec 14, 2017 00:01 GMT

Phase III MURANO results presented for the first time as one of six late breaking abstracts during the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta

Welsh Government renews commitment to eliminate hepatitis C with support from health organisations

Press Releases   •   Dec 07, 2017 00:01 GMT

MAIDENHEAD, Dec. 07, 2017 – AbbVie is sponsoring a roundtable meeting, Chaired by The Hepatitis C Trust and sponsored by Ynys Môn Assembly Member, Rhun ap Iorwerth, to consider how the NHS in Wales can be supported to meet the Government’s commitment to eliminating hepatitis C as a major public health threat in Wales by 2030.1 

The meeting will bring together a range of stakeholders to identify the barriers and opportunities to implementing a new hepatitis framework, published in October by the Welsh Government. 2 The framework aims to prevent the transmission of hepatitis C (HCV) through identifying, testing and treating people currently infected with HCV and those who are engaged in behaviours likely to lead to further transmission of the virus. Included within the framework is a focus on effective and sustained community outreach services to engage people not already in contact with services. 

“Despite being a preventable and now curable condition, hepatitis C has remained a challenge for us to eliminate in many communities including some of the most vulnerable members of society, such as those affected by homelessness, substance misuse, and people from countries where the virus is highly prevalent”, said Dr Brendan Healy, Consultant in Infectious Diseases & Microbiology at the University Hospital of Wales and blood-borne virus lead for Wales, who contributed to the drafting of the new framework.

“Treating people in all of these communities is not only good for them but also good for the population as a whole because it reduces the burden on the healthcare system and it decreases the chances of people in Wales becoming infected (regardless of which part of society they inhabit). The programme in Wales is ambitious and well respected because of its success to date in eradicating hepatitis C from many individuals. There’s still a lot more that needs to be done though, including securing more support and funding, to make sure we’re reaching those who remain undiagnosed and preventing the virus from spreading to others.” 

It is estimated that 12,000 people in Wales are chronically infected with hepatitis C 3 - a curable blood-borne virus that can cause fatal liver damage and cancer if left untreated.4 Wales is among the most highly affected regions in the UK. 1 

Latest Public Health Wales figures suggest there has been an increase in recent transmission of hepatitis C among people who inject drugs in Wales; particularly among younger populations injecting amphetamines that do not have a long-term history of drug misuse. 5

Others thought to be at risk include migrant populations (in particular South Asian and Eastern European communities), men who have sex with men, prisoners, and homeless people. 6 

Speaking at the meeting, Charles Gore, Chief Executive, The Hepatitis C Trust said: “The relatively recent introduction of direct acting anti-viral drugs provides the opportunity, which is so rare in public health, to actually eliminate the virus as a major public health threat. “Wales has the opportunity to lead the way by implementing its framework, which is dedicated to attaining the World Health Organization’s target for eliminating the virus. With a highly motivated and experienced clinical community, and a host of organisations committed to the task, Wales is well-placed to deliver against its ambition.”

The Blood Borne Virus Service led by Dr Healy and his team at the University Hospital of Wales is providing outreach support in the Cardiff & Vale community that they hope to see rolled out across Wales. The service offers ‘one stop shops’ for assessment, diagnosis, liver surveillance and treatment of hepatitis C. These also include drop-in clinics for information, testing and advice.

About The Hepatitis C Trust 

The Hepatitis C Trust is the national UK charity for hepatitis C. It is committed to eliminating hepatitis C as a major public health threat, by 2030, and it provides information, support and representation for all those affected by the disease. Started by patients, almost all of its governing Board of Trustees, paid staff and volunteers are patients. www.hepctrust.org.uk Helpline: 0845 223 4424

References

1 Public Health England, Hepatitis C in England 2017 report, 28 July 2017 

2 Welsh Health Circular (WHC/2017/048), Attaining the WHO targets for eliminating hepatitis (B and C) as a significant threat to public health, 16 October, 2017. http://cardiffandvaleapb.org/download/mediaresources/WHC-2017-048-Attaining-the-WHO-targets-for-eliminating-hepatitis-B-and-C-as-a-significantthreat-to-public-health.pdf (Accessed: November 2017) 

3 Public Health Wales, Hepatitis C, 2017. Available at: www.wales.nhs.uk/sitesplus/888/page/43746 (Date Accessed: November 2017) 

4 Harris, R. J. et al. 2016. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat, 23: 631–643

5 Homar, L. F. et al. Evidence for an increase in recent transmission of hepatitis C amongst people who inject drugs in Wales www.wales.nhs.uk/sitesplus/documents/888/HepC_PWID_SMS_ESCAIDE2015_f.pdf (Accessed: November 2017) 

6 The Hepatitis C Trust, Hepatitis C in Wales: Perspectives, challenges & solutions, 2015. http://hepctrust.org.uk/sites/default/files/Hepatitis%20C%20in%20Wales%20- %20Perspectives%2C%20Challenges%20%26%20Solutions_0.pdf (Accessed: November 2017)

AXHCV171710 Date of preparation: November 2017

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

MAIDENHEAD, Dec. 07, 2017 – AbbVie is sponsoring a roundtable meeting, Chaired by The Hepatitis C Trust and sponsored by Ynys Môn Assembly Member, Rhun ap Iorwerth, to consider how the NHS in Wales can be supported to meet the Government’s commitment to eliminating hepatitis C as a major public health threat in Wales by 2030.

Read more »

Contacts 9 contacts

  • Press Contact
  • Director of Communications & Patient Relations
  • dlopgwxibigrevsqtnbyedenbjgeaneina.whiteui@adttdkhbbvie.cohqm
  • 07876 391 429

  • Press Contact
  • Head of Patient Relations & Brand Communication
  • phliqhilippa.mylanning@aivbbbsviskhue.sdcom
  • 07818 428 081

  • Press Contact
  • Senior Corporate Communications Manager
  • Policy comms; Transparency; Corporate projects
  • matthew.worrall@abbvie.com
  • 07464 652 626

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Oncology & Dermatology
  • daiykgnielableyxosbpba.sswmithiz@aohbbsnhdqnptvie.ckioyguacoyidom
  • 07825 078 734

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Oncology
  • bqjooyanrhkfna.jezones@abbkqfqarkeurvibve.coslowm
  • 07795 590 344

  • Press Contact
  • Corporate Communications Specialist
  • Digital communication
  • flgporajenprce.chinnvw@abbvie.bpcotfbem
  • 07990 089 023

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Pan-Immunology & AbbvieCare
  • kkchroyexjerylscetwa.pesmijweesqitzbntcherhfxm@abbvie.cgcom
  • 07500 786 466

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Immunology - Gastroenterology & Rheumatology
  • nadtsymitatzlikpnwe.bennexrzett@abfqekbvgpieljue.cmfom
  • 07818 428 074

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Hepatitis C; Paediatrics; Neurology
  • sarah.beck@abbvie.com
  • 07818 428 111

About AbbVie UK

We're a company that takes on the toughest health challenges.

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

Address

  • AbbVie UK
  • AbbVie House, Vanwall Business Park, Vanwall Road
  • SL6 4UB Maidenhead
  • United Kingdom